Stereotaxis STXS recently announced the regulatory submissions for the MAGiC catheter, which is seeking marketing clearance in Europe and the United States.These submissions follow successful initial clinical results in an ongoing trial.

The company looks forward to working collaboratively with the regulatory agencies during their review of the submissions and hopes to make MAGiC catheter benefits available to patients and physicians soon.

Price Performance

In the past six months, STXS shares have gained 53.8% compared with the industry’s rise of 14.9%. The S&P 500 increased 14.9% in the same time frame.

Image Source: Zacks Investment Research

More on MAGiC Catheter

The Stereotaxis MAGiC catheter is a robotically guided magnetic ablation device intended for use in minimally invasive cardiac ablation treatments. Based on nearly two decades' worth of experience with over 100,000 procedures using robotically navigated ablation catheters, MAGiC includes several features intended to improve patient safety, procedural effectiveness and efficiency, and the doctor-patient experience.

The MAGiC catheter was used for the first time on humans earlier in 2024 as part of a clinical investigation that involved many centers. A renowned journal for electrophysiology received stellar preliminary data from the first 20 surgeries, indicating 100% acute effectiveness and no side effects. The regulatory submissions contained these results.

The MAGiC catheter's CE Mark and PMA Supplement filings are the result of a comprehensive process that involves design, development, manufacture, and testing. The catheter is the first of many interventional devices that Stereotaxis is developing, and it provides a framework for future advancements.

After obtaining regulatory permissions, Stereotaxis plans to commercially release the MAGiC catheter for robotic electrophysiologists’ use.

Industry Prospects

Per a report by Global Market Insights, the global electrophysiology market was estimated at $5.6 billion in 2022 and is expected to grow more than $17.1 billion by 2032 at a growth rate of 12%.

The rising prevalence of cardiac arrhythmia and heart failure among the population is likely to boost the market growth opportunities.

With the market potential for electrophysiology, Stereotaxis is likely to boost its business with its MAGiC catheter as it finds application in robotic electrophysiology.

Stereotaxis Inc. Price

Stereotaxis Inc. price | Stereotaxis Inc. Quote

Zacks Rank & Other Stocks to Consider

STXS carries a Zacks Rank #2 (Buy) at present.